It was a battle of the companies with drugs for transthyretin-mediated amyloidosis on the first day of the J.P. Morgan 2026 ...

For individuals with major depressive disorder (MDD) that does not respond to pharmacotherapy, recent decisions by the U.S.

Newco Tecregen AG has raised CHF10 million (US$12.5 million) to advance a novel way of regenerating the thymus in order to boost T-cell production and stimulate recovery of the immune system following ...

Med-tech financing activity rebounded sharply in 2025, with total reported capital raised climbing to $39.55 billion, nearly ...

Jun Chen, a tenured associate professor of bioengineering at the Samueli School of Engineering at the University of ...

Immorta Bio Inc. has reported new data demonstrating that its combination therapy of Senovax, a first-in-class senolytic ...

Incregen Therapeutics LLC has advanced INC-118, a glucose-dependent insulinotropic polypeptide (GIP) ligand antagonist ...

Ukko Inc. has announced plans to initiate clinical trials with UKK-0018 for peanut allergy in the first half of this year.

The concept of the 3 Rs – reducing, refining and replacing animal research – has been championed since the 1950s, when ...

Amgen Inc. has swooped on two European cancer specialists, buying Dark Blue Therapeutics Ltd. for up to $840 million plus ...

Radiopharma-focused Aktis Oncology Inc. priced its recently upsized IPO, selling 17.65 million shares at $18 apiece, the high ...

The value of biopharma deals involving nonprofit partners declined sharply over the past several years, falling to about $127 ...